Early cancer-detection company developing blood-based, AI-driven screening tests, starting with colorectal cancer.
Early cancer-detection company developing blood-based, AI-driven screening tests, starting with colorectal cancer.
In one line: An AI-driven, blood-test rival to Exact Sciences' Cologuard.
Moat: narrow (data, IP / patents). AI/multiomics platform trained on large blood-sample datasets aims to detect early-stage cancer signals.
Headquarters: South San Francisco, California · Founded: 2013 · Employees: 3
Size Freenome (FRNM) is a United States Health Care company (Medical Specialties) with a market value of $1.08B, the 2174th largest of 3,085 United States companies the cockpit tracks. Shares closed at $9.73 on 18 Nov 2026.
Growth The operating margin is 36.2% (peer median 11.6%).
Valuation It trades at 4.7× enterprise value to sales against a peer median of 4.0× (9th most expensive of 20).
Capital Return on invested capital runs 13.1 points above its cost of capital (7.6% WACC).
Next results Next results expected around 3 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | |
|---|---|---|---|
| Revenue | $183M | $0 | $0 |
| Revenue growth | — | — | — |
| Gross profit | $177M | $0 | $0 |
| EBITDA | $72.5M | -$2.98M | -$494,000 |
| Net income | $59.2M | $837,468 | $1.91M |
| Free cash flow | n/a | -$864,650 | -$713,260 |
| Capital expenditure | n/a | $0 | $0 |
| Total debt | $202M | $0 | $0 |
| Company | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g |
|---|---|---|---|---|---|---|
| Freenome FRNM | $1.08B | n/a | n/a | 36% | 4.7× | n/a |
| Guardant Health GH | $19.6B | +26% | +42% | -39% | 15.9× | n/a |
| Natera NTRA | $42.0B | +41% | +37% | -9% | 14.1× | n/a |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | FRNM | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -30.8% | -5.1% | 2nd lowest of 21 |
| Distance from 52-week high | -44.4% | -29.4% | 5th lowest of 21 |
| Operating margin | 36.2% | 11.6% | 2nd highest of 20 |
| EV / Sales | 4.7× | 4.0× | 9th most expensive of 20 |
| ROIC minus cost of capital | +13.1 pp | +0.3 pp | 7th highest of 19 |
| EV / EBITDA | 11.8× | 8.5× | 3rd most expensive of 7 |
| Net debt / EBITDA | -3.1× | 1.7× | least indebted of 7 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Freenome FRNM | United States | $1.08B | n/a | n/a | 36% | 4.7× | n/a | n/a |
| CLASSYS 214150.KS | South Korea | $1.08B | -60% | +16% | 43% | 4.0× | -9.2% | +34.5% |
| Integra LifeSciences IART | United States | $1.08B | -10% | +1% | 12% | 1.7× | 5.9% | +3.6% |
| Alphatec ATEC | United States | $1.10B | -14% | +15% | -3% | 1.9× | n/a | n/a |
| Mingyue Optical Lens 301101.SZ | China | $1.07B | -4% | +14% | 25% | 6.3× | 8.8% | +8.8% |
| Guangzhou Hexin Instrument 688622.SS | China | $1.06B | +21% | -29% | -74% | 85.0× | n/a | n/a |
| SI-BONE SIBN | United States | $1.06B | +59% | +14% | -8% | 4.3× | n/a | n/a |
| Alpha Tau Medical DRTS | United States | $1.11B | +7% | n/a | n/a | n/a | n/a | n/a |
| IRadimed IRMD | United States | $1.05B | -9% | +11% | 32% | 11.1× | 18.5% | +21.5% |
| Beijing Strong Biotechnologies 300406.SZ | China | $1.13B | -4% | -4% | 36% | 5.8× | 1.7% | +9.9% |
| Castle Biosciences CSTL | United States | $1.03B | +67% | +10% | -7% | 2.1× | 57.7% | +40.6% |
| Eckert & Ziegler EUZ.DE | Germany | $1.03B | -2% | +4% | 26% | 2.7× | 7.7% | +12.1% |
| Shandong Weigao Orthopaedic Device 688161.SS | China | $1.14B | -29% | -6% | 18% | 4.7× | 11.3% | -3.5% |
| Beijing Wandong Medical Technology 600055.SS | China | $1.03B | -26% | -11% | -33% | 3.0× | n/a | n/a |
| Inno Laser Technology 301021.SZ | China | $1.03B | -33% | +17% | 9% | 11.1× | 50.8% | +8.6% |
| PHC 6523.T | Japan | $1.02B | +34% | +3% | 8% | 0.9× | -4.0% | +3.5% |
| Amoy Diagnostics 300685.SZ | China | $1.01B | -15% | +7% | 34% | 4.7× | 4.9% | +10.4% |
| Edan Instruments 300206.SZ | China | $1.00B | -19% | +14% | 17% | 2.5× | 6.9% | -2.9% |
| Ceribell CBLL | United States | $995M | +42% | +31% | -70% | 8.3× | n/a | n/a |
| Tandem Diabetes Care TNDM | United States | $1.19B | +13% | +7% | -2% | 1.4× | n/a | n/a |
| INKON Life Technology 300143.SZ | China | $985M | -23% | +22% | 12% | 3.1× | 10.7% | +12.9% |